{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:57:34Z","timestamp":1787986654177,"version":"build-2784847793"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Bipolar disorder (BD) is chronic psychiatric disorder associated with significant impairment in psychosocial functioning and quality of life. Although current pharmacological treatments for BD have improved its clinical management, many patients do not achieve remission, particularly those suffering from bipolar depression. In addition, available treatments are associated with a myriad of potential adverse effects, which highlights the need for novel therapeutic agents that can be effective for both phases of the illness with a reduced side effect burden. Cariprazine is a novel antipsychotic that is a dopamine D2\/D3 partial agonist with a preference for D3 receptors. In this review, we examine the pharmacological properties, clinical efficacy and tolerability profile of cariprazine in patients with BD, taking into account the latest clinical trials data. We also review <jats:italic>post hoc<\/jats:italic> analyses addressing clinically relevant subgroups and symptom domains in BD. Current evidence suggests efficacy for cariprazine 3\u201312 mg\/day in the treatment of acute manic and mixed episodes; for bipolar depression, the efficacy of cariprazine appears to be dose-related, with doses of 1.5\u20133 mg\/day beneficial as monotherapy. Cariprazine is overall well-tolerated by patients in both manic and depressive episodes. Its most common side effects relative to placebo include akathisia, extrapyramidal symptoms and nausea. There are no metabolic concerns reported with cariprazine use. In summary, the latest evidence suggests that cariprazine is an effective and safe treatment option for BD.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.769897","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:24:10Z","timestamp":1639463050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Andr\u00e9","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Keramatian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1399-5618.2008.00604.x","article-title":"Quality of life in bipolar disorder patients: a comparison with a general population sample","volume":"10","author":"Gutierrez-Rojas","year":"2008","journal-title":"Bipolar Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14656566.2018.1426746","article-title":"An overview of pharmacotherapy for bipolar I disorder","volume":"19","author":"Morsel","year":"2018","journal-title":"Expert Opin Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0165-0327(03)00161-7","article-title":"Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up","volume":"81","author":"Goldberg","year":"2004","journal-title":"J Affect Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jad.2016.11.021","article-title":"The difficult lives of individuals with bipolar disorder: A review of functional outcomes and their implications for treatment","volume":"209","author":"Gitlin","year":"2017","journal-title":"J Affect Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/YIC.0b013e32836435e2","article-title":"The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective: a review","volume":"28","author":"Dols","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","article-title":"Comparative tolerability of dopamine D2\/3 receptor partial agonists for schizophrenia","volume":"34","author":"Keks","year":"2020","journal-title":"CNS Drugs."},{"key":"B11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bdi.12850","article-title":"Cariprazine in the treatment of bipolar disorder: a systematic review and meta-analysis","volume":"22","author":"Pinto","year":"2020","journal-title":"Bipolar Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D(3) receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"Leggio","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov Today."},{"key":"B17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00210-008-0311-x","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15","volume":"378","author":"Gyertyan","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","author":"Gyertyan","year":"2011","journal-title":"Neurochem Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-012-2906-7","article-title":"Cariprazine (RGH-188), a D(3)-preferring dopamine D(3)\/D(2) receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats","volume":"226","author":"Roman","year":"2013","journal-title":"Psychopharmacology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.psychres.2017.02.067","article-title":"Substance abuse in patients with bipolar disorder: A systematic review and meta-analysis","volume":"253","author":"Messer","year":"2017","journal-title":"Psychiatry Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/ijnp\/pyx038","article-title":"Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model","volume":"20","author":"Duric","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2045125320905752","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther Adv Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2174\/1871527317666180828120256","article-title":"Cariprazine in bipolar depression and mania: state of the art","volume":"17","author":"Mazza","year":"2018","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"B25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1017\/S1092852913000850","article-title":"Role of alpha1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5144","DOI":"10.2174\/1381612822666160701084447","article-title":"The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders","volume":"22","author":"De Berardis","year":"2016","journal-title":"Curr Pharm Des."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine. A broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety","volume":"38","author":"Laszlovszky","year":"2021","journal-title":"Adv Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1517\/17425255.2011.575061","article-title":"Pharmacokinetics and metabolism update for some recent antipsychotics","volume":"7","author":"Caccia","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/14656566.2019.1660319","article-title":"Efficacy and safety of cariprazine in the treatment of bipolar disorder","volume":"20","author":"Saraf","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/TCRM.S35137","article-title":"A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia","volume":"9","author":"Caccia","year":"2013","journal-title":"Ther Clin Risk Manag."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2147\/DDDT.S188760","article-title":"Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine","volume":"13","author":"Kiss","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC's of dopamine receptor partial agonists\u2014aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int J Clin Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2020.1795126","article-title":"Up-to-date expert opinion on the safety of recently developed antipsychotics","volume":"19","author":"Orsolini","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J Affect Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","author":"Yatham","year":"2020","journal-title":"Int Clin Psychopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bdi.12852","article-title":"Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study","volume":"22","author":"Earley","year":"2020","journal-title":"Bipolar Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1176\/appi.ajp.2018.18070824","article-title":"Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study","volume":"176","author":"Earley","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2017.03.032","article-title":"Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II\/III studies","volume":"215","author":"Earley","year":"2017","journal-title":"J Affect Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jad.2019.11.098","article-title":"A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression","volume":"263","author":"Earley","year":"2020","journal-title":"J Affect Disord."},{"key":"B44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jad.2021.03.076","article-title":"Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression","volume":"288","author":"Citrome","year":"2021","journal-title":"J Affect Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","article-title":"Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II\/III trials","volume":"25","author":"Vieta","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"20m02611","DOI":"10.4088\/PCC.20m02611","article-title":"Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications","volume":"22","author":"Yatham","year":"2020","journal-title":"Prim Care Companion CNS Disord"},{"key":"B47","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jad.2019.07.020","article-title":"Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials","volume":"257","author":"McIntyre","year":"2019","journal-title":"J Affect Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1017\/S1092852919001287","article-title":"Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies","volume":"25","author":"McIntyre","year":"2020","journal-title":"CNS Spectr."},{"key":"B49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/S1092852921000213","article-title":"Effects of cariprazine on cognition in patients with bipolar mania or mixed states: post hoc analysis from 3 randomized, controlled phase III studies","volume":"26","author":"McIntyre","year":"2021","journal-title":"CNS Spectr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/03007995.2021.1932446","article-title":"The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial","volume":"37","author":"Vieta","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajp.2017.01.020","article-title":"Prevalence of metabolic syndrome and its clinical correlates among patients with bipolar disorder","volume":"26","author":"Kumar","year":"2017","journal-title":"Asian J Psychiatr."},{"key":"B53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies","volume":"28","author":"Thase","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","author":"Zimnisky","year":"2013","journal-title":"Psychopharmacology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2215-0366(17)30046-9","article-title":"Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study","volume":"4","author":"Yatham","year":"2017","journal-title":"Lancet Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1600-0447.2007.01055.x","article-title":"Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis","volume":"116","author":"Torres","year":"2007","journal-title":"Acta Psychiatr Scand Suppl"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.769897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T06:24:14Z","timestamp":1639463054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.769897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2021.769897"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.769897","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"article-number":"769897"}}